Literature DB >> 18789857

Catechol-O-methyltransferase Val158Met polymorphism in relation to aggressive schizophrenia in a Korean population.

Youl-Ri Kim1, Jeong Hyun Kim, Se Joo Kim, Dongeun Lee, Sung Kil Min.   

Abstract

We examined the association between the Catechol-O-methyltransferase (COMT) Val158Met polymorphism and aggressive schizophrenia. The sample included 61 aggressive schizophrenic patients as well as 104 non-aggressive patients from psychiatric hospitals and 415 healthy volunteers in South Korea. In the case-control comparisons, there was no significant association between the aggressive schizophrenic patients and the COMT Val158Met polymorphism. Looking only at the subgroup of aggressive schizophrenic patients, however, we found a dose-dependent relationship between the Met allele and verbal aggression. In this subgroup, the Met carriers showed a higher verbal aggression score than those with the Val/Val homozygote. These findings support the hypothesized moderating role of the COMT gene in the aggressive behaviour in some schizophrenic patients, though they do not support the existence of a direct association between the COMT Val158Met polymorphism and aggressive schizophrenia case status in the Korean population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18789857     DOI: 10.1016/j.euroneuro.2008.07.009

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  13 in total

1.  Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Authors:  Colm M P O'Tuathaigh; Brian P Kirby; Paula M Moran; John L Waddington
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

Review 2.  Neurobiology of aggression and violence in schizophrenia.

Authors:  Michael Soyka
Journal:  Schizophr Bull       Date:  2011-09       Impact factor: 9.306

3.  The COMT Met158 allele and violence in schizophrenia: a meta-analysis.

Authors:  Savita G Bhakta; Jian-Ping Zhang; Anil K Malhotra
Journal:  Schizophr Res       Date:  2012-07-10       Impact factor: 4.939

4.  Analysis of COMT Val158Met polymorphisms and methylation in Chinese male schizophrenia patients with homicidal behavior.

Authors:  Yikai Hu; Chenghu Li; Yangfan Wang; Qinhan Li; Yidong Liu; Shengde Liao; Peiqing Cao; Hongmei Xu
Journal:  Int J Legal Med       Date:  2018-02-17       Impact factor: 2.686

Review 5.  The Role of a Catechol-O-Methyltransferase (COMT) Val158Met Genetic Polymorphism in Schizophrenia: A Systematic Review and Updated Meta-analysis on 32,816 Subjects.

Authors:  Thelma Beatriz González-Castro; Yazmin Hernández-Díaz; Isela Esther Juárez-Rojop; María Lilia López-Narváez; Carlos Alfonso Tovilla-Zárate; Ana Fresan
Journal:  Neuromolecular Med       Date:  2016-03-28       Impact factor: 3.843

6.  External validity of studies on aggressive behavior in patients with schizophrenia: systematic review.

Authors:  Tilman Steinert; Karen Hamann
Journal:  Clin Pract Epidemiol Ment Health       Date:  2012-08-23

7.  No Association Between Functional Polymorphisms in COMT and MTHFR and Schizophrenia Risk in Korean Population.

Authors:  Ho Jin Kang; Byeong Moo Choe; Seong Hwan Kim; Seung-Rak Son; Kyoung-Mu Lee; Byoung Gwon Kim; Young-Seoub Hong
Journal:  Epidemiol Health       Date:  2010-12-24

Review 8.  Gene-sex interactions in schizophrenia: focus on dopamine neurotransmission.

Authors:  Sean C Godar; Marco Bortolato
Journal:  Front Behav Neurosci       Date:  2014-03-06       Impact factor: 3.558

9.  No evidence of an association between A218C polymorphism of the tryptophan hydroxylase 1 gene and aggression in schizophrenia in a Korean population.

Authors:  Youl-Ri Kim; Joo Young Lee; Sung Kil Min
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

10.  A meta-analysis of the Val158Met COMT polymorphism and violent behavior in schizophrenia.

Authors:  Jay P Singh; Jan Volavka; Pál Czobor; Richard A Van Dorn
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.